ETF Channel: Analysts See 19% Upside for iShares US Pharmaceuticals ETF IHE

Friday, Mar 20, 2026 8:53 am ET1min read
CRMD--
EOLS--
IHE--
RAPP--

Analysts see nearly 19% upside for the iShares US Pharmaceuticals ETF (IHE) based on the average analyst 12-month forward target price for its underlying holdings. Three holdings with notable upside to their analyst target prices are Evolus Inc, CorMedix Inc, and Rapport Therapeutics Inc, with potential gains of 220%, 129%, and 90%, respectively. IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index and holds large and mid-cap drug manufacturers, with analysts expecting gains in chronic-disease treatments, specialty biologics, oncology, and neurology.

ETF Channel: Analysts See 19% Upside for iShares US Pharmaceuticals ETF IHE

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet